Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for DNA methyltransferase inhibitor, 5- aza- 2'- deoxycytidine
Most Correlated Studies
- MCF7 cells gene expression after 72hr treatment with 5-Aza-CdR or DZNep
- Breast cancer cell line MCF7 treated with 3-deazaneplanocin A or 5-aza-2-deoxycytidine
- Embryonal carcinoma cell line response to 5-aza deoxycytidine or cisplatin
- 5-aza-2-deoxycytidine (5-aza-dC)-demethylated breast and colon cancer cells and DNMT-KO HCT116 cells
- Oral squamous cell carcinoma cell lines treated with 5-aza-2'-deoxycytidine (AzC)
Most Relevant Literature
- A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, exacerbates neurotoxicity and upregulates…
- Decitabine, a DNA methyltransferase inhibitor, reduces P-glycoprotein mRNA and protein expressions a…
- Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells…
- Anti-invasive effects of decitabine, a DNA methyltransferase inhibitor, through tighteni…
- The role of decitabine for the treatment of acute myeloid leukemia.
Most Relevant Clinical Trials
- 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
- PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS
- Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid …
- Decitabine for High-Risk Sickle Cell Disease
